1. A Study of Multiple Therapies in Biomarker-Selected Patients With Resectable Stages IB-III Non-Small Cell Lung Cancer - Full Text View - ClinicalTrials.gov [Internet]. [cited 2023 Mar 2]. Available from: 〈https://clinicaltrials.gov/ct2/show/NCT04302025〉.
2. A Study of Neoadjuvant/Adjuvant Durvalumab for the Treatment of Patients With Resectable Non-small Cell Lung Cancer - Full Text View - ClinicalTrials.gov [Internet]. [cited 2023 Feb 28]. Available from: 〈https://www.clinicaltrials.gov/ct2/show/NCT03800134〉.
3. A Study of Neoadjuvant Atezolizumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Patients With Resectable Stage II, IIIA, or Select IIIB Non-Small Cell Lung Cancer (IMpower030) - Full Text View - ClinicalTrials.gov [Internet]. [cited 2023 Feb 28]. Available from: 〈https://www.clinicaltrials.gov/ct2/show/NCT03456063〉.
4. A Study of Neoadjuvant Chemotherapy Plus Nivolumab Versus Neoadjuvant Chemotherapy Plus Placebo, Followed by Surgical Removal and Adjuvant Treatment With Nivolumab or Placebo for Participants With Surgically Removable Early Stage Non-small Cell Lung Cancer - Full Text View - ClinicalTrials.gov [Internet]. [cited 2023 Feb 28]. Available from: 〈https://www.clinicaltrials.gov/ct2/show/NCT04025879〉.
5. A Study of Selpercatinib (LOXO-292) in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer (LIBRETTO-001) - Full Text View - ClinicalTrials.gov [Internet]. [cited 2023 Mar 7]. Available from: 〈https://clinicaltrials.gov/ct2/show/NCT03157128〉.